New hope for Tough-to-Treat blood cancer? early trial tests drug combo
NCT ID NCT07278856
Summary
This early-stage trial aims to find a safe and effective dose of a drug called ruxolitinib when given alongside standard chemotherapy (CHOP) for adults newly diagnosed with a rare type of T-cell lymphoma. The main goal is to see if the combination is safe and tolerable. If patients respond well to the initial treatment, they may continue taking ruxolitinib alone as a maintenance therapy to try to keep the cancer under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.